Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons

The cardiovascular health study

Jorge Kizer, David Benkeser, Alice M. Arnold, Kenneth J. Mukamal, Joachim H. Ix, Susan J. Zieman, David S. Siscovick, Russell P. Tracy, Christos S. Mantzoros, Christopher R. Defilippi, Anne B. Newman, Luc Djousse

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

BACKGROUND-: Adiponectin shows opposite associations with adverse outcomes in healthy middle-aged populations (lower risk) and cohorts with prevalent cardiovascular disease, heart failure, or advanced age (higher risk). METHODS AND RESULTS-: In a population-based study of older adults, we examined the relationships of total and high-molecular-weight adiponectin with mortality among subgroups defined by baseline cardiovascular status: No cardiovascular disease, heart failure, or atrial fibrillation (group 1); cardiovascular disease but no heart failure/atrial fibrillation (group 2); and heart failure/atrial fibrillation (group 3). We found significant differences in the associations with all-cause mortality across the groups. The association in group 1 was U-shaped; increasing levels of total adiponectin up to 12.4 mg/L were associated with lower mortality after adjustment for confounders (hazard ratio=0.81 per 1 SD [95% confidence interval, 0.65-0.95]), but above this cut point, higher levels conferred greater risk (hazard ratio=1.19 [95% confidence interval, 1.12-1.27]). Further adjustment for diabetes mellitus or insulin resistance, protection against which has been proposed to mediate the beneficial relationships of adiponectin with outcome, attenuated the association in the lower range. There was no significant association in group 2, but in group 3, total adiponectin showed a direct adjusted association. Additional adjustment for putative metabolic/inflammatory intermediates suggested a direct association for group 2, and magnified the one for group 3 (hazard ratio=1.31 [1.15-1.50]). Results were similar for high-molecular-weight adiponectin and for cardiovascular mortality. CONCLUSIONS-: Adiponectin exhibits distinct associations with mortality in elders, which shift from U-shaped to flat to direct with greater baseline cardiovascular dysfunction but become more consistently adverse after accounting for metabolic/inflammatory factors presumed to be favorably regulated by the adipokine. These findings advance understanding of the adiponectin paradox as it relates to older adults.

Original languageEnglish (US)
Pages (from-to)2951-2961
Number of pages11
JournalCirculation
Volume126
Issue number25
DOIs
StatePublished - Dec 18 2012
Externally publishedYes

Fingerprint

Adiponectin
Molecular Weight
Mortality
Health
Heart Failure
Atrial Fibrillation
Cardiovascular Diseases
Confidence Intervals
Adipokines
Population
Insulin Resistance
Diabetes Mellitus
Odds Ratio

Keywords

  • adiponectin
  • aging
  • mortality

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons : The cardiovascular health study. / Kizer, Jorge; Benkeser, David; Arnold, Alice M.; Mukamal, Kenneth J.; Ix, Joachim H.; Zieman, Susan J.; Siscovick, David S.; Tracy, Russell P.; Mantzoros, Christos S.; Defilippi, Christopher R.; Newman, Anne B.; Djousse, Luc.

In: Circulation, Vol. 126, No. 25, 18.12.2012, p. 2951-2961.

Research output: Contribution to journalArticle

Kizer, J, Benkeser, D, Arnold, AM, Mukamal, KJ, Ix, JH, Zieman, SJ, Siscovick, DS, Tracy, RP, Mantzoros, CS, Defilippi, CR, Newman, AB & Djousse, L 2012, 'Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: The cardiovascular health study', Circulation, vol. 126, no. 25, pp. 2951-2961. https://doi.org/10.1161/CIRCULATIONAHA.112.135202
Kizer, Jorge ; Benkeser, David ; Arnold, Alice M. ; Mukamal, Kenneth J. ; Ix, Joachim H. ; Zieman, Susan J. ; Siscovick, David S. ; Tracy, Russell P. ; Mantzoros, Christos S. ; Defilippi, Christopher R. ; Newman, Anne B. ; Djousse, Luc. / Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons : The cardiovascular health study. In: Circulation. 2012 ; Vol. 126, No. 25. pp. 2951-2961.
@article{ee9aa01749fa4c71817acc75ea8c1b26,
title = "Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: The cardiovascular health study",
abstract = "BACKGROUND-: Adiponectin shows opposite associations with adverse outcomes in healthy middle-aged populations (lower risk) and cohorts with prevalent cardiovascular disease, heart failure, or advanced age (higher risk). METHODS AND RESULTS-: In a population-based study of older adults, we examined the relationships of total and high-molecular-weight adiponectin with mortality among subgroups defined by baseline cardiovascular status: No cardiovascular disease, heart failure, or atrial fibrillation (group 1); cardiovascular disease but no heart failure/atrial fibrillation (group 2); and heart failure/atrial fibrillation (group 3). We found significant differences in the associations with all-cause mortality across the groups. The association in group 1 was U-shaped; increasing levels of total adiponectin up to 12.4 mg/L were associated with lower mortality after adjustment for confounders (hazard ratio=0.81 per 1 SD [95{\%} confidence interval, 0.65-0.95]), but above this cut point, higher levels conferred greater risk (hazard ratio=1.19 [95{\%} confidence interval, 1.12-1.27]). Further adjustment for diabetes mellitus or insulin resistance, protection against which has been proposed to mediate the beneficial relationships of adiponectin with outcome, attenuated the association in the lower range. There was no significant association in group 2, but in group 3, total adiponectin showed a direct adjusted association. Additional adjustment for putative metabolic/inflammatory intermediates suggested a direct association for group 2, and magnified the one for group 3 (hazard ratio=1.31 [1.15-1.50]). Results were similar for high-molecular-weight adiponectin and for cardiovascular mortality. CONCLUSIONS-: Adiponectin exhibits distinct associations with mortality in elders, which shift from U-shaped to flat to direct with greater baseline cardiovascular dysfunction but become more consistently adverse after accounting for metabolic/inflammatory factors presumed to be favorably regulated by the adipokine. These findings advance understanding of the adiponectin paradox as it relates to older adults.",
keywords = "adiponectin, aging, mortality",
author = "Jorge Kizer and David Benkeser and Arnold, {Alice M.} and Mukamal, {Kenneth J.} and Ix, {Joachim H.} and Zieman, {Susan J.} and Siscovick, {David S.} and Tracy, {Russell P.} and Mantzoros, {Christos S.} and Defilippi, {Christopher R.} and Newman, {Anne B.} and Luc Djousse",
year = "2012",
month = "12",
day = "18",
doi = "10.1161/CIRCULATIONAHA.112.135202",
language = "English (US)",
volume = "126",
pages = "2951--2961",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "25",

}

TY - JOUR

T1 - Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons

T2 - The cardiovascular health study

AU - Kizer, Jorge

AU - Benkeser, David

AU - Arnold, Alice M.

AU - Mukamal, Kenneth J.

AU - Ix, Joachim H.

AU - Zieman, Susan J.

AU - Siscovick, David S.

AU - Tracy, Russell P.

AU - Mantzoros, Christos S.

AU - Defilippi, Christopher R.

AU - Newman, Anne B.

AU - Djousse, Luc

PY - 2012/12/18

Y1 - 2012/12/18

N2 - BACKGROUND-: Adiponectin shows opposite associations with adverse outcomes in healthy middle-aged populations (lower risk) and cohorts with prevalent cardiovascular disease, heart failure, or advanced age (higher risk). METHODS AND RESULTS-: In a population-based study of older adults, we examined the relationships of total and high-molecular-weight adiponectin with mortality among subgroups defined by baseline cardiovascular status: No cardiovascular disease, heart failure, or atrial fibrillation (group 1); cardiovascular disease but no heart failure/atrial fibrillation (group 2); and heart failure/atrial fibrillation (group 3). We found significant differences in the associations with all-cause mortality across the groups. The association in group 1 was U-shaped; increasing levels of total adiponectin up to 12.4 mg/L were associated with lower mortality after adjustment for confounders (hazard ratio=0.81 per 1 SD [95% confidence interval, 0.65-0.95]), but above this cut point, higher levels conferred greater risk (hazard ratio=1.19 [95% confidence interval, 1.12-1.27]). Further adjustment for diabetes mellitus or insulin resistance, protection against which has been proposed to mediate the beneficial relationships of adiponectin with outcome, attenuated the association in the lower range. There was no significant association in group 2, but in group 3, total adiponectin showed a direct adjusted association. Additional adjustment for putative metabolic/inflammatory intermediates suggested a direct association for group 2, and magnified the one for group 3 (hazard ratio=1.31 [1.15-1.50]). Results were similar for high-molecular-weight adiponectin and for cardiovascular mortality. CONCLUSIONS-: Adiponectin exhibits distinct associations with mortality in elders, which shift from U-shaped to flat to direct with greater baseline cardiovascular dysfunction but become more consistently adverse after accounting for metabolic/inflammatory factors presumed to be favorably regulated by the adipokine. These findings advance understanding of the adiponectin paradox as it relates to older adults.

AB - BACKGROUND-: Adiponectin shows opposite associations with adverse outcomes in healthy middle-aged populations (lower risk) and cohorts with prevalent cardiovascular disease, heart failure, or advanced age (higher risk). METHODS AND RESULTS-: In a population-based study of older adults, we examined the relationships of total and high-molecular-weight adiponectin with mortality among subgroups defined by baseline cardiovascular status: No cardiovascular disease, heart failure, or atrial fibrillation (group 1); cardiovascular disease but no heart failure/atrial fibrillation (group 2); and heart failure/atrial fibrillation (group 3). We found significant differences in the associations with all-cause mortality across the groups. The association in group 1 was U-shaped; increasing levels of total adiponectin up to 12.4 mg/L were associated with lower mortality after adjustment for confounders (hazard ratio=0.81 per 1 SD [95% confidence interval, 0.65-0.95]), but above this cut point, higher levels conferred greater risk (hazard ratio=1.19 [95% confidence interval, 1.12-1.27]). Further adjustment for diabetes mellitus or insulin resistance, protection against which has been proposed to mediate the beneficial relationships of adiponectin with outcome, attenuated the association in the lower range. There was no significant association in group 2, but in group 3, total adiponectin showed a direct adjusted association. Additional adjustment for putative metabolic/inflammatory intermediates suggested a direct association for group 2, and magnified the one for group 3 (hazard ratio=1.31 [1.15-1.50]). Results were similar for high-molecular-weight adiponectin and for cardiovascular mortality. CONCLUSIONS-: Adiponectin exhibits distinct associations with mortality in elders, which shift from U-shaped to flat to direct with greater baseline cardiovascular dysfunction but become more consistently adverse after accounting for metabolic/inflammatory factors presumed to be favorably regulated by the adipokine. These findings advance understanding of the adiponectin paradox as it relates to older adults.

KW - adiponectin

KW - aging

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=84871337477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871337477&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.112.135202

DO - 10.1161/CIRCULATIONAHA.112.135202

M3 - Article

VL - 126

SP - 2951

EP - 2961

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 25

ER -